Skip to main content Skip to home page
 

Monoclonal Antibody Treatment

The FDA has approved two monoclonal antibody medications with emergency use authorization for treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

These medications include the Eli Lilly product Bamlinivimab and the Regeneron product Casirivimab/Imdevimab.
  These medications are only for COVID-19 positive patients who:
  • are in their first 7 days of symptoms
  • are at high-risk for hospitalization, and meet any of the criteria below
Patients who meet any of this criteria must schedule an appointment with Deaconess Clinic LIVE to determine if they are good candidates for the medication.  Schedule your appointment here

Criteria for patients who may benefit from this treatment
Adults (weighing at least 88 pounds)
  • Age ≥ 65 
  • BMI ≥ 35   (BMI calculator)
  • Chronic Kidney Disease
  • Diabetes
  • Immunosuppressive disease
  • Currently receiving immunosuppressive treatment
  • Age ≥ 55 AND have at least one of the following
    • Cardiovascular disease
    • Hypertension
    • COPD/chronic respiratory disease
Adolescents ages 12-17 (weighing at least 88 pounds)
  • BMI ≥ 85th percentile
  • Chronic Kidney Disease
  • Diabetes
  • Immunosuppressive disease
  • Currently receiving immunosuppressive treatment
  • Sickle cell disease
  • Congenital or acquired heart disease
  • Neurodevelopmental disorders, such as Cerebral palsy
  • Medical related technological dependence (i.e. tracheostomy, gastrostomy)
  • Asthma or other chronic respiratory disease requiring daily maintenance medications
If you believe you or a loved one may be a candidate for this treatment, schedule an appointment with Deaconess Clinic LIVE to determine if they are good candidates for the medication.  Schedule your appointment here.
Top Back to top